Blog

The DEA telehealth flexibilities that let controlled-substance programs prescribe without a prior in-person exam expire December 31, 2026, and the Special Registration rule meant to replace them is still not final. That leaves every ADHD, MAT, testosterone, and controlled-substance mental health program roughly 120 days to plan for three very different endings. This is the contingency plan: the scenario tree, the exposure map, the fallback network, and the decision dates.

Platform pricing is the most-hidden data in telehealth, which is exactly why the few published numbers get quoted everywhere. Here are the four pricing models vendors actually use, the public data points, the five hidden costs that wreck TCO math, and a worksheet that turns any quote into a number you can compare.

Every comparison of white-label telehealth platforms is written by a vendor, and this one is too. So we set rules: name who each platform genuinely serves best, say plainly when that is not us, and quote pricing only where a real number is public. Nine platforms, one table, no scoring theater.

Testosterone prescribing for women is growing faster than almost any corner of hormone care, up nearly 59% year over year by recent prescribing analyses, and it sits almost entirely off-label, which means the clinical governance bar is the product. For operators already serving midlife women, this is the natural deepening of the hormone relationship. For everyone else, it is a masterclass in how labs-first, evidence-honest program design turns a sensitive niche into a durable one. Here is the blueprint.

The half-year funding recap just landed: the strongest first half since 2021, capital concentrating in fewer and larger deals, the busiest acquisition quarter in five years, and AI woven through nearly every major check. Read as a market report, it is interesting. Read as a map of where sophisticated builders are placing bets, it is a strategy memo for every telehealth operator. Here is the operator's read.

You do not need to be a physician to build a telehealth company. The MSO and friendly-PC model is the well-established structure that lets non-clinician founders build, fund, and scale virtual-care brands while licensed clinicians own the medicine. This is the plain-language explainer: what each entity does, how the pieces fit, why the structure exists, and how to set it up so it supports growth instead of slowing it.

Direct-to-consumer telehealth has its own working vocabulary. Some terms are clinical, some are regulatory, some are technical, and some are commercial. A working fluency across all of them is what separates founders who can move quickly from founders who get stuck in vendor conversations. This is the operator's glossary of the 75 terms every DTC telehealth founder, operator, marketer, and clinical lead should know in 2026.

Mid-2026 is the most interesting moment DTC telehealth has had since the pandemic. The compounded GLP-1 era is ending on a hard timeline, branded-access partnerships are the new floor, retail and Big Tech entered the market, EHRs are pivoting to agentic AI, and several adjacent indications became real categories. This is the operator's field report on where the industry is, what changed, and what to build next.

The first 100 patients in a telehealth program are the most valuable feedback loop the brand will ever get. They are the only cohort small enough to know deeply and large enough to draw real patterns from. Used well, they shape every meaningful decision for the next 1,000. This is the founder's playbook for learning from them on purpose.

Mental health is one of the strongest 2026 entry categories for DTC telehealth. The clinical evidence base is mature, the DEA flexibilities support controlled-substance care, the patient base is ready, and the four main sub-program shapes (therapy, medication management, ketamine for treatment-resistant depression, psychiatric continuity-of-care) each have a clear operating model. This is how to design a real program, not a portal that markets itself as one.

A well-built clinical advisory board is one of the highest-leverage assets a DTC telehealth brand can put in place. It strengthens credibility, sharpens clinical protocols, supports compliance posture, recruits providers, and grounds the brand in real care. This is how to design, recruit, and run a board that earns its place on the homepage.

The DEA and HHS extended COVID-era telehealth flexibilities for controlled substances through 2026, keeping the door open for telehealth programs that prescribe Schedule II to V medications without a prior in-person visit. The extension is operational, not philosophical, and the programs you can responsibly build under it have very specific guardrails.

Before launching a DTC telehealth business, founders need to choose the right business model. Cash-pay, insurance, subscription, and hybrid models each change conversion, provider operations, billing, pharmacy workflows, support burden, and retention.

A DTC telehealth tech stack should connect the full patient journey before launch: landing pages, intake, consent, provider review, EHR, payments, pharmacy, labs, portal, support, analytics, and internal operations.

Starting a DTC telehealth business in 2026 takes more than a landing page and a provider. Founders need to define the program, provider model, intake, billing, pharmacy, patient portal, compliance posture, support workflows, and launch metrics before the first patient starts care.

White-label telehealth buyers often face a core architecture choice: all-in-one stack or modular infrastructure. The right answer depends on launch speed, control, integrations, clinical model, data ownership, and how much change the brand expects after launch.

The next telehealth program should not be chosen only by search volume or medication margin. Strong specialty expansion depends on clinical complexity, repeat-care potential, acquisition fit, operational load, and whether the patient journey can be made coherent.

Telehealth menopause programs need more than a consult button. In 2026, the strongest programs combine thoughtful intake, patient education, provider review, and ongoing follow-up into one coordinated care experience.

Regenerative peptides are not a single product. They are a portfolio of substances with different indications, patient profiles, and operational implications. Here is a practical map for telehealth teams thinking about a peptide program in 2026 and 2027.

Hair-loss programs are a strong fit for subscription telehealth, but only when the intake, provider review, billing, refill logic, and patient expectations are designed to work together.